Thrombosis
News
How ruxolitinib reduces thrombosis in MPNs
Preclinical research helps explain how the JAK1/2 inhibitor ruxolitinib can reduce thrombosis in patients with myeloproliferative neoplasms (MPNs...
News
FDA approves antidote for factor Xa inhibitors
The US Food and Drug Administration (FDA) has granted accelerated approval for andexanet alfa (Andexxa®), the first antidote for the reversal of...
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
News
Study shows increased risk of VTE among earthquake evacuees
New research has revealed a link between earthquake evacuation and venous thromboembolism (VTE). The study showed that people who spent the night...
News
Blood type linked to death risk after trauma
Having type O blood is associated with high death rates in severe trauma patients, according to a study published in Critical Care. Researchers...
Conference Coverage
NHLBI seeks to accelerate hemostasis/thrombosis research
SAN DIEGO – About half of hemostasis/thrombosis research is basic in nature.
News
Single injection could treat hemophilia B long-term
Cell therapy could produce lasting effects in hemophilia B, according to a group of researchers. They genetically modified induced pluripotent...
Conference Coverage
Does warfarin cause acute kidney injury?
SAN DIEGO – Consider increased monitoring of renal function in certain patients.
News
PI3K inhibitors could treat HHT
Preclinical research suggests PI3K inhibitors could treat hereditary hemorrhagic telangiectasia (HHT). Experiments in mice and patient samples...
News
Fostamatinib produces responses in ITP
Fostamatinib has produced “clinically meaningful” responses in adults with persistent or chronic immune thrombocytopenia (ITP), according to...
Conference Coverage
Impaired kidney function no problem for dabigatran reversal
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.